Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Abstract

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.

Keywords:

• Burkitt’s lymphoma
• polatuzumab
• Lymphoma
• anti CD79b
• resistant lymphoma

Data Sharing Statement

Data and materials are available upon reasonable request.

Ethical Approvals

Written consent was taken from the patient for research and data publication. The case report was approved by the Hamad Medical Corporation’s Medical Research Center under the Number (MRC-04-22-535).

Acknowledgment

Open Access funding is provided by the Qatar National Library.

Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

Qatar National Library.